Page 12 - ஹென்ரிச் ஹெய்ன் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) Results presented at the 2020 San Antonio Breast Cancer Symposium confirm the relevance of screening for HER2+ CTCs from blood samples in patients with a HER2 negative primary tumor biopsy to optimize treatment strategy and patient outcome BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 10, 2020 /PRNewswire/ Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today new data from the DETECT study program. These data focused on women with HER2 negative metastatic breast cancer (MBC) based on primary tumor biopsy, and HER2 + CTCs. The results of this large program demonstrate that screening for HER2+ CTCs, in the blood samples of these patients, is an important tool to guide therapy decisions and improve patient outcomes. Furthermore, the randomized DETECT III phase III study, discussed in a poster spotlight session during the 2020 San Antonio Breast Cancer Symposium, shows that adding reference HER2 targeted TKI (tyrosine kinase inhibitor) lapatinib t

San antonioUnited statesCecilia simonelliKostenloser wertpapierhandelTanjan fehmLinda pavyHeinrich heine universityHead of the department gynecology obstetricsUs food drug administrationChina national medical products administrationResearch useMenarini groupAntonio breast cancer symposiumSilicon biosystemsMenarini silicon biosystemGlobal medical affairs head